SEC Form 4 · accession 0001104659-18-046292

Crinetics Pharmaceuticals, Inc. · CRNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Versant Affiliates Fund V, L.P.

10% Owner

Versant Venture Capital V, L.P.

10% Owner

Versant Ophthalmic Affiliates I, L.P.

10% Owner

Versant Venture Capital V (Canada), LP

10% Owner

Period of report

Jul 20, 2018

Accepted (ET)

Jul 20, 2018 · 4:34 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001658247

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F6	Jul 20, 2018	C	2,557,392	—	A	2,557,392	I	See Footnotes
Common Stock^F1,F3,F6	Jul 20, 2018	C	76,927	—	A	76,927	I	See Footnotes
Common Stock^F1,F4,F6	Jul 20, 2018	C	85,253	—	A	85,253	I	See Footnotes
Common Stock^F1,F5,F6	Jul 20, 2018	C	194,629	—	A	194,629	I	See Footnotes
Common Stock^F1,F2,F6	Jul 20, 2018	C	412,534	—	A	2,969,926	I	See Footnotes
Common Stock^F1,F3,F6	Jul 20, 2018	C	12,409	—	A	89,336	I	See Footnotes
Common Stock^F1,F4,F6	Jul 20, 2018	C	13,736	—	A	98,989	I	See Footnotes
Common Stock^F1,F5,F6	Jul 20, 2018	C	31,396	—	A	226,025	I	See Footnotes

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F1,F2,F6	—	Jul 20, 2018	C	8,413,817	D	—	—	Common Stock	2,557,392	I
Series A Preferred Stock^F1,F3,F6	—	Jul 20, 2018	C	253,091	D	—	—	Common Stock	76,927	I
Series A Preferred Stock^F1,F4,F6	—	Jul 20, 2018	C	280,485	D	—	—	Common Stock	85,253	I
Series A Preferred Stock^F1,F5,F6	—	Jul 20, 2018	C	640,332	D	—	—	Common Stock	194,629	I
Series B Preferred Stock^F1,F2,F6	—	Jul 20, 2018	C	1,357,240	D	—	—	Common Stock	412,534	I
Series B Preferred Stock^F1,F3,F6	—	Jul 20, 2018	C	40,826	D	—	—	Common Stock	12,409	I
Series B Preferred Stock^F1,F4,F6	—	Jul 20, 2018	C	45,192	D	—	—	Common Stock	13,736	I
Series B Preferred Stock^F1,F5,F6	—	Jul 20, 2018	C	103,293	D	—	—	Common Stock	31,396	I

Explanation of responses

F1The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date.
F2These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.
F3These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.
F4These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.
F5These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), LP ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.
F6This report on Form 4 is jointly filed by VVC V, VAF V, VOA and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.